Three key words for the development of pharmaceutical industry: innovation, global competition and medical services

[pharmaceutical network market analysis] in the view of the industry, with the gradual recovery of the drug market and medical market, the key words for the development of the pharmaceutical industry will still be innovation, global competition and medical services Key words 1: innovation In recent years, the mode of drug purchase in China has changed significantly While the volume purchase policy intensifies the reshuffle of the pharmaceutical industry, the price of generic drugs will return to the reasonable level of the production link, and at the same time, it forces pharmaceutical enterprises to increase R & D and transform to innovation According to the data, in the first three quarters of 2019, 118 of the 165 pharmaceutical enterprises (including chemical pharmaceutical, traditional Chinese medicine and biological products, excluding some enterprises whose data are not statistically available) in A-share of China have increased their R & D investment compared with the previous year In the first three quarters of this year, the R & D expenditure of these 118 enterprises increased by 37.60% on average In the long run, enterprises with weak innovation ability and poor competitiveness will be eliminated in the future The industry suggests that pharmaceutical enterprises with core technology and innovation capabilities should be embraced In addition, cro / CMO has a higher short-term prosperity, and innovative drug companies can gain more long-term value As for the long-term growth potential, we need to see the ability of enterprises to internationalize Key word 2: global competition In recent years, the global competition in the pharmaceutical industry has been increasing, and relevant domestic R & D and production enterprises are inclined to innovative products The rapid participation of global competitors (accepting overseas clinical data) will promote the R & D and innovation of domestic enterprises, at the same time, improve the quality and price of domestic drugs, and accelerate the supply side reform of the domestic pharmaceutical industry In addition, domestic pharmaceutical companies have also taken the initiative to speed up M & A integration and layout global innovation fields For example, on the evening of February 9, Yuanda pharmaceutical announced the completion of the acquisition of shares in the US NASDAQ listed company oncosec medical After the completion of the transaction, COSCO pharma and its affiliated company sirtex group will hold 52.8% of the shares of oncosec, of which, COSCO Pharma holds 44% and sirtex 8.8% The industry believes that M & A integration brings synergy effects in innovative R & D, product pipeline and sales, which is the highlight of this transaction After the completion of the transaction, the three parties will give full play to their advantages in their respective fields and achieve the investment effect of "1 + 1 + 1 > 3" In the view of the insiders, the acquisition is an important part of the global innovation strategy of Yuanda pharmaceutical, which helps the company overtake in the global innovation wave and promotes the implementation of the global innovation strategy of the company Key words three: medical service and medical service The increase of per capita disposable income, the aging of population and the rise of chronic diseases are the three main driving factors for the development of China's medical service industry In recent years, with the promotion of favorable policies and the aggravation of aging, people's consumption level has been upgraded, and the domestic medical industry has grown rapidly According to frost Sullivan report, in 2026, the market scale of China's large health industry will increase to 26.8 trillion yuan, with a compound annual growth rate of 12.0%; the total medical expenditure in China will reach 11403.1 billion yuan, with a compound annual growth rate of 9.4%; it is expected that the annual per capita disposable income in 2026 will reach 513 million yuan, with a compound annual growth rate of 8.0% In addition, data shows that in 2016, the number of people over 60 years old is about 230.9 million, accounting for 16.7% of the total population of China, and these figures are expected to reach 271.5 million and 18.6% in 2026 As the overall metabolism and immune capacity of the elderly gradually decline, they have a greater chance of suffering from chronic diseases, resulting in high cost of long-term medication and scientific disease management.